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ABSTRACT
Zika fever is an acute infectious disease caused by the Zika virus (ZIKV) of the Flaviviridae family and Flavi-
virus genus. It is transmitted by day-time active Aedes mosquitoes, and potentially by sexual contacts, blood 
transfusion, and from mother to foetus (resulting in microcephaly in a child). ZIKV was first isolated from 
a macaque monkey in the Zika forest in Uganda in 1947. The first case of the Zika fever in a human was 
recorded in Nigeria in 1954. Until 2007 only 14 cases of the disease were confirmed worldwide. In 2007, 
there was an outbreak of the Zika fever in Micronesia (Yap Island) with an estimated 5,000 cases. Between 
2013 and 2015 a further outbreak of the disease occurred in the Pacific islands: in French Polynesia, New 
Caledonia, Cook Islands, Easter Island, and Solomon Islands. In 2015, the Zika fever spread to Brazil and 
more than 20 other countries in the South and Central America. Until March 2016, an estimated 1.6 million 
autochthonous cases of Zika have been reported globally, with approximately 1.5 million cases recorded 
in Brazil. Typically, 80% of Zika infections are asymptomatic. The most common symptoms of the disease 
include fever, maculopapular rash, muscle and joint pain, conjunctivitis. Zika fever can be diagnosed on 
the basis of clinical signs (it must be differentiated from dengue, chikungunya), ZIKV identification is also 
possible by the application of polymerase chain reaction in acutely ill patients and the detection of specific 
IgM and IgG antibodies to ZIKV. Until today, there is no effective antiviral treatment or an effective vaccine 
against Zika fever (in case of an infection only symptomatic treatment is applied). In August 2016 in Rio de 
Janeiro (Brazil) Summer Olympic Games will take place, attracting thousands of athletes and spectators. 
The fight against the Zika fever and the race against time have gained momentum. 
(Int Marit Health 2016; 67, 1: 31–37)
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INTRODUCTION
Zika fever is an acute infectious disease caused by the 
Zika RNA virus (ZIKV) belonging to family Flaviviridae, genus 
Flavivirus, which are also the aetiological factors of dengue, 
yellow fever, Japanese encephalitis, and West Nile fever [1]. 
ZIKV is transmitted by day-time active female Aedes mosqui-
toes (mainly Aedes aegypti and Aedes albopictus), vectors of 
dengue, chikungunya, yellow fever, Japanese encephalitis, 
and West Nile fever [2]. The true extent of ZIKV vectors is still 
unknown. The distribution of Aedes mosquitos is now the 
most extensive ever recorded due to global trade and travel. 
It is reported in Sub-Saharan Africa, South and South-East 
Asia, North Australia, Oceania, South and Central America, 
southern states of the United States, and also in southern 
Europe (A. aegypti in Georgia, southern Russia, Madeira; A. al-
bopictus in Italy, France, Spain, Greece, Croatia, Montenegro, 
Albania, Bulgaria, southern Russia) [3, 4]. ZIKV is not endemic 
in Poland because Aedes mosquitoes transmitting the virus 
are not present in the territory of our country; however, there 
is a potential risk of importing the disease from Zika endemic 
areas, e.g. South and Central America because of a growing 
popularity of transcontinental travel among Polish people. 
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Potentially, ZIKV is also transmitted by sexual contacts, 
blood transfusion, and from mother to foetus (causing micro-
cephaly in a child) [5]. Until March 2016, there have been 
3 cases of ZIKV infection which might indicate that the virus 
can be spread through sexual contact. In 2008, an American 
biologist had been repeatedly bitten by mosquitoes while 
working in Senegal; a week after his return to the United 
States he developed symptoms of Zika fever (the infection 
was confirmed by laboratory tests). Soon a  woman with 
whom the biologist had unprotected sex after returning to 
the United States (she had not travelled outside the country 
that year) developed similar symptoms (ZIKV infection was 
confirmed). In December 2013, in French Polynesia ZIKV 
was found in the semen of a man, after he had fallen ill with 
Zika fever. In February 2016, in Texas (United States) a man 
contracted Zika fever after sexual contact with a woman 
who had recently returned from endemic region in South 
America [6–8]. Until now, there are no confirmed cases of 
ZIKV transmission through blood transfusion. A potential risk 
is suspected based on positive tests for ZIKV in 42 blood do-
nors studied during the Zika outbreak in French Polynesia at 
the turn of the year 2013/2014. At the time of blood trans-
fusion they were asymptomatic; 11 of the infected donors 
reported symptoms of Zika fever after their donation [9]. 
In 2015, in Brazil ZIKV was detected in the amniotic fluid of 
2 pregnant women whose foetuses had microcephaly [10]. 
There have been further cases of the disease from this 
country (confirmed by polymerase chain reaction [PCR] tests 
of tissues of miscarriages and brain tissues from newborns 
with microcephaly, who had died shortly after birth) [11]. 
The number of microcephaly cases among newborn chil-
dren in Brazil, the country with the highest number of ZIKV 
infections in the world, has increased from 150 cases per 
year in the period 2010–2014 to 1,248 in 2015 (as of 
28 November 2015). The highest prevalence of microcephaly 
among newborns was recorded in the state of Pernambuco 
(646; the reported rate 77 times higher than in the previous 
5 years) [12]. On 2 January 2016, the Ministry of Health of 
Brazil announced that the number of suspected cases of 
microcephaly across the country had reached 3,174 cases, 
including 38 deaths. The worst affected regions are north-
eastern states of Pernambuco, Paraiba and Bahia, where 
about 1% of newborns are suspected of being microcephalic 
[13]. According to World Health Organisation (WHO), a link 
between ZIKV and microcephaly is strongly suspected but 
still not scientifically proven [14].
EPIDEMIOLOGY
Zika virus was first isolated from a macaque monkey in 
the Zika forest in Uganda in 1947 [15]. In 1948, ZIKV was 
isolated from Aedes mosquito (A. africanus), which was 
considered to be a vector for Zika transmission [16]. Over 
the next decades the ZIKV was isolated from other mos-
quitos of the Aedes genus: A. aegypti, A. apicoargenteus, 
A. luteocephalus, A. vitattus, A. furcifer, A. albopictus [17]. 
The first symptomatic case of the Zika fever in a human was 
recorded in Nigeria in 1954 [18]. Until 2007 only 14 cases 
of the disease were confirmed worldwide [17]. The first out-
break of the Zika fever occurred in Micronesia (Yap Island) in 
2007. During the outbreak Duffy et al. [17] collected blood 
samples from 557 residents of Yap Island; 414 (74%) of the 
tested individuals had IgM antibody against ZIKV and 156 
(38%) of the infected, with a mean age of 36 (61% women; 
usually the elderly), reported symptoms of the illness during 
the outbreak period. Researchers estimated that 5,005 of 
the 6,892 Yap residents, who were 3 years of age or older, 
became infected with ZIKV in 2007 [17]. These were the 
first cases of the disease recorded outside Africa or Asia 
[19]. Between 2013 and 2015 further outbreaks occurred 
in some Pacific islands: in French Polynesia, New Caledonia, 
Cook Islands, Easter Island, and Solomon Islands [12]. In 
December 2013 ZIKV was suspected to be responsible for 
an estimated 19,000 cases of dengue-like syndrome in French 
Polynesia [20]. In 2015, Zika fever spread to Brazil and more 
than 20 other countries in South and Central America. Until 
February 2016, an estimated 1.6 million autochthonous 
cases of Zika have been reported globally, mainly in South and 
Central America (including approximately 1.5 million cases in 
Brazil alone, over 30,000 cases in Columbia, more than 4,600 
cases in Venezuela) (Table 1), less commonly in Africa (over 
7,000 in Cape Verde) and on the islands of Oceania (Tonga, 
American Samoa, Samoa) [21]. As of 17 February 2016, the 
Centres for Disease Control and Prevention (CDC) reported 
82-travel associated Zika fever cases in the United States, 
with no locally acquired vector-borne infections [22]. Single 
cases of imported Zika infections have also been recorded in 
Europe [23, 24], China [25], and Australia [26]. A continuing 
expansion of the infection vector to all parts of the world may 
result in the occurrence of new ZIKV outbreaks, especially in 
densely populated urban areas [27]. On 1 February 2016, 
the WHO declared the ZIKV outbreak to be a Public Health 
Emergency of International Concern. The WHO declaration may 
potentially reduce the number of visitors to the Rio Olympic 
Games in 2016 [28].
CLINICAL MANIFESTATIONS
Eighty per cent of Zika infections are asymptomatic [29]. 
Clinical manifestations of Zika fever are similar to other 
arboviral infections, especially to dengue and chikungun-
ya, therefore Zika fever should be first differentiated from 
these two conditions (Table 2). Other illnesses presenting 
with fever and skin rash, which should be differentiated 
from the Zika fever are measles, rubella, O’nyong-nyong, 
leptospirosis, rickettsioses.  
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Table 1. Cumulative Zika suspected and confirmed autochtho-
nous cases in the Americas, 2015–2016. Source: WHO IHR 
Regional Contact Point for the Americas; the Ministry of Health 
websites, 25 February 2016
Country/territory Suspected 
cases
Confirmed 
cases
Deaths from 
Zika cases
South America
Brazil1 72,062 534 4
Colombia 35,399 1,612 3
Venezuela 4,696 4 1
Suriname 1,097 6 4
French Guyana 790 99 0
Ecuador 0 25 0
Paraguay 0 6 0
Bolivia 0 1 0
Guyana 0 1 0
Central America
El Salvador 8,584 3 0
Honduras 4,590 2 0
Guatemala 278 105 0
Mexico 0 93 0
Panama 0 86 0
Nicaragua 0 66 0
Costa Rica 0 3 0
Caribbean
Martinique 6,050 12 0
Haiti 329 5 0
Dominican Republic 305 18 0
Guadeloupe 221 25 0
United States  
Virgin Island
59 4 0
Puerto Rico 0 30 0
Saint Martin 0 7 0
Barbados 0 7 0
Aruba 0 4 0
Others 0 7 0
Total 134,460 2,765 12
1The suspected cases in Brazil are unofficial. Brazilian Ministry of Health repor-
ted minimum 497,523 and 1,482,701 as maximum estimated cases.
The incubation period of the Zika fever after a bite by 
ZIKV-infected mosquito ranges from 3 to 12 days and is 
similar to other infections caused by flaviviruses [2]. Clinical 
signs typically persist for 2–7 days [12]. The most common 
clinical manifestations include low-grade fever, transient 
joint pain (mainly smaller joints of hands and feet), macu-
lopapular rash (covering the face, the neck, the trunk, the 
extremities: first the upper and next the lower), non-purulent 
conjunctivitis, muscle pain, mild cephalea, vertigo, retro-
orbital pain, malaise. The illness usually has a mild and 
self-limiting course [30, 31].
There is a link between Zika infection and neurologic 
conditions in newborn children (microcephaly) and adults 
(Guillain-Barré syndrome [GBS]) [32]. In the French Polyne-
sian outbreak, 73 cases of GBS (a rapid onset of muscle 
weakness which can progress to paralysis) occurred in 
a  population of 270,000; GBS may have been associ-
ated with the ZIKV [12, 33]. Some countries affected by 
Zika outbreaks have recorded an increase in GBS cases, 
including 3 deaths due to Zika related GBS reported in 
Colombia [34].   
In December 2015, the European CDC issued a com-
prehensive update on the possible association of ZIKV with 
congenital microcephaly. Data suggest that newborns of 
mothers who became infected with the ZIKV during the first 
trimester of pregnancy are at an increased risk for micro-
cephaly [12]. 
Microcephaly is a pathological condition defined as a re-
duction in head circumference of two standard deviations 
(£ 2 SD) below the mean for age, sex and race. Before the 
Zika outbreak microcephaly occurred in 0.07% of newborns 
in Brazil, it now occurs in 1–2% [35]. Apart from micro-
cephaly, other prenatally diagnosed foetal defects of the 
central nervous system were observed in pregnant women 
infected with ZIKV, including intracranial calcification, ven-
triculomegaly and cerebral hypoplasia [36]. In Pernambuco 
state in Brazil, among 55 suspected microcephalic babies 
of which 40 cases were related to ZIKV, about 40% also 
exhibited ocular malformations (retinal atrophy, pigment 
alteration) [37]. 
 Interim Zika fever case definition (according to Pan 
American Health Organisation) [38]:
 — Suspected case: patient with rash or elevated body 
temperature (> 37.2°C) with at least one of the following 
symptoms (not explained by other medical conditions): 
arthralgia or myalgia, non-purulent conjunctivitis or con-
junctival hyperaemia, headache or malaise. 
 — Confirmed case: a suspected case of Zika fever with 
laboratory positive result for ZIKV. 
DIAGNOSTICS
Zika diagnosis can be based on anamnesis (travel to 
endemic areas), clinical signs (however, it is difficult to 
diagnose Zika fever based on clinical signs alone due to 
overlaps with other arboviral infections that are endemic 
to similar areas, e.g. dengue, chikungunya) [32], RNA ZIKV 
identification by PCR on serum in acutely ill patients (< 7 
days after symptoms onset) and detection of specific IgM 
and IgG antibodies to ZIKV with ELISA test (≥ 4 days after 
symptoms onset) (Fig. 1). The serological diagnosis of ZIKV 
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Table 2. Comparison of clinical signs of Zika fever, dengue, and chikungunya. Source: Prof. Carlos Brito, Federal University of  
Pernambuco, Brazil, December 2015
Clinical signs Zika fever Dengue Chikungunya
Fever (duration) No fever or subfebrile tempera-
ture ≤ 38°C (1–2 days)
Over 38°C
(4–7 days)
Over 38°C
(2–3 days)
Skin rash On 1st on 2nd day after the  
onset — 90% cases
On 4th day after the onset 
— 30–50% cases
On 2nd–5th after the onset  
— 50% cases
Myalgia (frequency) ++/+++ +++/+++ +/+++
Arthralgia (frequency) ++/+++ +/+++ +++/+++
Arthralgia (intensity) Mild/moderate Mild Moderate/severe
Joint swelling Common, mild Rare Common, moderate/severe 
Non-purulent conjunctivitis 50–90% cases rarely 30% cases
Lymphadenopathy + ++ ++
Hepatomegaly – +++ –
Leucopoenia/thrombopoenia – +++ +++
Cephalea (frequency and intensity) ++ +++ ++
Pruritus Moderate/severe Mild Mild
Neurological symptoms More common than in dengue 
and chikungunya
Rare Rare (most common  
in newborns)
Figure 1. Algorithm for detection of Zika virus (ZIKV) suspected cases. Source: Pan American Health Organisation. World Health Organi-
sation Regional Office for the Americas, 29 June 2015, Centres for Disease Control and Prevention. Division of Vector-Borne Diseases, 
07 February 2016; CHIKV — chikungunya virus; DENV — dengue virus; RT-PCR — real time polymerase chain reaction
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may be impeded by cross-reactivity of ZIKV antibodies with 
other viruses. The methods currently available to test for 
Zika antibodies cross-react especially with dengue anti-
bodies. An IgM-positive result in a dengue or Zika ELISA 
test can only be considered indicative of a recent flavivirus 
infection. Plaque-reduction neutralisation tests (PRNT) can 
be performed and may be specific [39]. Some authors have 
reported using PCR of the urine to diagnose ZIKV, but this 
has not been independently confirmed [40].
Pregnant women who have travelled to areas with ZIKV 
transmission should be tested for suspected ZIKV infection 
[39] (Fig. 2) and foetal ultrasound scan should be per-
formed. Babies born to ZIKV-positive mothers also should 
be screened for ZIKV infection. CDC recommends testing of 
infants with both molecular and serologic assays (RT-PCR, 
IgM ELISA, PRNT), as well as physical investigation for 
neurologic abnormalities, splenomegaly, hepatomegaly, 
skin lesions, hearing evaluation, eye examination. Test-
ing should be done for any abnormalities encountered in 
other congenital viral infections such as toxoplasmosis, 
rubella, cytomegalovirus, and herpes simplex virus infec-
tion (TORCH syndrome) [29]. In order to differentiate Zika 
fever from other arboviral infections attention should be 
paid to laboratory tests results, especially the levels of 
leukocytes and platelets, which are within normal range 
in case of a Zika infection, but tend to be reduced in case 
of dengue or chikungunya.  
 TREATMENT AND PREVENTION
Only symptomatic treatment is applied to manage the 
Zika infection (antipyretics, analgesics, antipruritics and 
medications maintaining nutrition and hydration). As yet, 
there are no antiviral medications available for ZIKV [41]. 
Nonsteroidal anti-inflammatory drugs should be used only 
when dengue has been ruled out to reduce the risk of 
bleeding. Paracetamol is the drug of choice in pregnancy 
(aspirin is contraindicated). In case of central nervous sys-
tem complications (microcephaly, GBS) neurological med-
ications are introduced [32]. Although very rare, intensive 
care admission may be warranted for patients with signs 
of sepsis or multi-organ failure with the rise in fever, tachy-
cardia, hypotension, renal dysfunction, liver dysfunction, 
respiratory distress, coagulopathy [33].
To prevent the transmission of ZIKV, WHO recommends 
mosquito avoidance by using insect repellents (containing 
DEET, picaridin, or IR3535, considered safe in pregnant and 
breastfeeding women), wearing long-sleeved shirts and long 
trousers to cover the body, and using screens and mosquito 
nets to exclude flying insects from dwellings or sleeping 
areas [42, 43]. CDC also recommends that water contain-
ers found around households (potential breeding sites for 
mosquitoes) should be cleaned once a week and that larvae 
should be killed with recommended larvicides. CDC advises 
pregnant women against travelling to Zika endemic areas 
in the Caribbean, Central and South America [44]. Because 
of the suspicion that ZIKV may be sexually transmitted, 
travellers are recommended to avoid sexual contacts in 
Zika endemic regions or use condoms throughout the stay 
as well as 2 weeks after returning from countries with Zika 
transmission. Women who plan to get pregnant and their 
male partners should follow all the necessary safety precau-
tions in order to avoid mosquito bites [44]. Officials in Brazil, 
Figure 2. Algorithm for detection of Zika virus (ZIKV) suspected cases in asymptomatic, pregnant women. Source: Centres for Disease 
Control and Prevention. Division of Vector-Borne Diseases, 07 February 2016; PRNT — plaque-reduction neutralisation tests; rest 
abbreviations as in Figure 1
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Colombia, Ecuador, El Salvador and Jamaica have urged 
their female citizens to postpone pregnancies [45]. Men 
who have travelled to ZIKV affected areas who have a preg-
nant partner are advised to abstain from sexual activity or 
consistently use condoms during sex for the duration of the 
pregnancy [12]. To date, there have been no confirmed re-
ports of ZIKV transmission through breastfeeding, although 
it had been found in human milk. Breastfeeding does not 
need to be discontinued in Zika endemic areas; howev-
er, this route of transmission should not be ignored [29]. 
Because it is suspected that ZIKV may be potentially trans-
mitted via blood transfusion, precautions need to be taken 
to avoid the pathogen entering public blood banks (ZIKV 
screening) [5].
Effective vaccines exist for several flaviviruses (yellow 
fever, Japanese encephalitis, tick-borne encephalitis); how-
ever, there is no effective vaccine against ZIKV infection 
as yet [43], just as there are still no vaccines available 
against dengue, chikungunya and West Nile fever, the most 
widespread arthropod-borne viral diseases in the Western 
Hemisphere over the past 20 years [32]. Returned travel-
lers who have developed symptoms indicative of the Zika 
infection or other vector-borne disease manifesting with 
fever and skin rash within 3 weeks after coming back from 
a ZIKV endemic region are advised to contact their health 
care provider [12]. 
In August 2016 in Rio de Janeiro (Brazil) Summer Olym-
pic Games are going to take place, attracting thousands of 
athletes and spectators from all over the world. At the end 
of January 2016, Rio’s municipal administration announced 
plans to try to prevent the spread of the Zika infections during 
the Olympic Games in the city. The fight against the Zika fever 
and the race against time have gained momentum. 
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